Symposium 1: Drug transporters in clinical pharmacokinetics and drug-drug interactions

Prof Jashvant Unadkat, University of Washington, USA

Jashvant (Jash) Unadkat, Ph.D. is a Professor of Pharmaceutics in the School of Pharmacy at the University of Washington, Seattle. He received his Bachelors degree in Pharmacy (B.Pharm.) from the University of London (1977), his Ph.D. from the University of Manchester (1982) and his postdoctoral training at the University of California at San Francisco (1982-85). Dr. Unadkat's research interests are focused on elucidating the mechanisms of transport and metabolism of anti-AIDS and anti-cancer drugs. In particular his laboratory has been interested in metabolism and transport of drugs during pregnancy, and transport of drugs across the placental, intestinal and blood-brain barrier. Dr. Unadkat has published more than 140 peer-reviewed research papers. Dr. Unadkat is a fellow of AAPS, JSSX, and the founding member and the past chair (1999-2001) of the focus group of AAPS on Drug Transport and Uptake. Dr. Unadkat has been an Associate Editor for the Journal of Pharmaceutical Sciences, an Editor of *AAPS Journal.*, and a member of the NIH Pharmacology study section (2000-3). Dr. Unadkat is currently on the editorial board of J. Pharm. Sci and the *AAPS Journal*. Dr. Unadkat has organized or co-organized numerous national and international conferences on the role of transporters and pregnancy in disposition of drugs. http://sop.washington.edu/pharmaceutics/faculty-a-research/jashvant-unadkat.html

Prof William Elmquist, University of Minnesota, USA

William F. Elmquist is currently Professor and Department Head at the University of Minnesota, Department of Pharmaceutics. He received his professional pharmacy degree at the University of Florida, and a Pharm.D. and Ph.D. (pharmacokinetics) from the University of Minnesota. Dr. Elmquist has developed an internationally recognized research program in preclinical pharmacokinetics. This program has revolved around the examination of the mechanisms of drug distribution to target tissues, in particular the central nervous system (CNS). This research has studied the influence of active efflux transporters in the blood-brain barrier (BBB) on CNS drug distribution. As an offshoot of this research, much of the well-recognized effort from Dr. Elmquist's laboratory has dealt with the exploration and quantitative development of the microdialysis technique, employed at *in vitro*, intracerebral and intravascular sampling sites**.** An important project has examined the determinants of anticancer drug permeability in the blood-brain barrier. The effective treatment of many brain tumors is limited by inadequate delivery of the chemotherapy across the barriers of the CNS, and mechanisms for limited delivery of molecularly-targeted anti-tumor agents have been discovered and characterized at the blood-brain barrier. Long-term objectives of Dr. Elmquist's research include examining expression and regulation of transport systems in key tissues that influence drug disposition, and how variability in expression, either genetically or environmentally controlled, may contribute to variability in drug response in the patient.

Dr Dhiren Thakker, University of North Carolina, USA



Dr. Thakker is the Ferguson Distinguished Professor and Associate Dean for Economic Development and International Partnerships at the UNC Eshelman School of Pharmacy, the University of North Carolina at Chapel Hill. From 1998 to 2008, he served as the Associate Dean for Research and Graduate Education. He is a co-founder of Qualyst and Sphaera Pharma. Previously, he served as Director of Drug Metabolism Department at Glaxo Inc., Principle Investigator at the Center for Biologics, FDA, and had held multiple positions at the National Institutes of Health. He has Batchelor of Pharmacy from Bombay University, India, M.S. in Pharmaceutical Chemistry from Columbia University, New York, and Ph.D. in Biochemistry from the University of Kansas at Lawrence.

Prof Kim Brouwer, University of North Carolina, USA

Kim L.R. Brouwer, Pharm.D., Ph.D., is the William R. Kenan, Jr., Distinguished Professor and Chair of the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Dr. Brouwer received her B.S. in Pharmacy from Oregon State University, Pharm.D./residency training and a Ph.D. in Pharmaceutical Sciences/Pharmacokinetics from the University of Kentucky College of Pharmacy, and postdoctoral training in Pharmacology/Drug Metabolism prior to joining the UNC faculty in 1986. Dr. Brouwer directs an NIH-funded research program focused on hepatobiliary drug disposition, hepatic transport proteins, and development/refinement of *in vitro* models to predict *in vivo* hepatic drug disposition, drug interactions, and hepatotoxicity. She has expertise in developing mathematical models and applying modeling/simulation to aid in the analysis and interpretation of *in vitro* and *in vivo* data in adults and pediatrics. Dr. Brouwer was founding Director of the UNC Pharmacokinetics/Pharmacodynamics Fellowship Program and is Co-PI of a NIH-funded Postdoctoral Training Program in Clinical Pharmacology. She has published more than 160 research papers and book chapters, and is co-inventor of B-CLEAR®. She is a member of the International Transporter Consortium Steering Committee, and several editorial advisory boards including *Clinical Pharmacology and Therapeutics, CPT: Pharmacometrics & Systems Pharmacology,* and the *AAPS Journal*. Dr. Brouwer was elected an AAPS Fellow in 1998 and was recipient of the PHRMA Foundation Award in Excellence in Pharmaceutics in 2001.

Symposium 2: The Yin and Yang of Novel Receptor Drug Discovery Paradigms

Prof Alastair Stewart, The University of Melbourne

Alastair Stewart is a Professor of Pharmacology at the University of Melbourne with extensive experience in the field of respiratory and inflammation research. He has served on numerous peer review committees for NHMRC and the scientific advisory boards of several Australian Medical Research Institutes. His research interests focus on tissue remodelling in asthma and novel drugs targeting tissue remodelling in inflammation. His long-term interest in steroid pharmacology has also encompassed several studies in tumour biology. He is currently focussed on elucidating determinants of steroid sensitivity. His laboratory has a strong track record of Graduate Research training and he maintains wide interests in education, research, research training and research support structures.

Prof Andrew Tobin, University of Leicester, UK

Professor Andrew Tobin is a programme group leader at the Medical Research Council Toxicology Unit at Leicester in the UK. He has for many years studied G-protein coupled receptor signalling in particular the role of receptor phosphorylation. Recently his research has focused on addressing the link between in vitro pharmacology and signal transduction with in vivo animal behaviour. Andrew also has an appointment with the University of Leicester where he is the Director of the Centre for Translational Research. In this role he evaluates and supports translational projects from across the University. This includes cancer and cardiovascular programmes as well as his own malaria research programme.

Dr Laura Bohn, The Scripps Research Institute, Florida, USA

Laura Bohn, Ph.D. investigates drug actions at GPCRs, which play critical roles in how patients respond to various therapeutics, including the opioid analgesics and antipsychotic agents. Dr. Bohn received post-doctoral training at HHMI/Duke University Medical Center with Drs. Marc Caron and Robert Lefkowitz and was Pharmacology faculty at The Ohio State University. She is currently at the Scripps Research Institute in Jupiter, Florida where she is pursuing new therapies for the treatment of pain. Laura has received the SFN Career Development Award, the Joseph Cochin Young Investigator Award from CPDD and the John J. Abel Award in Pharmacology from ASPET/Pfizer.

Denise Wootten, Monash University

Dr. Denise Wootten is a Research Fellow in the Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Victoria, Australia. She completed a PhD in 2008 at the University of Birmingham in the UK under the supervision of Professor Mark Wheatley where she focused on structure and function of peptide hormone receptors for the neurohypophysial hormones, vasopressin and oxytocin. She then took up a postdoctoral position in molecular pharmacology with Professors and Patrick M. Sexton and Arthur Christopoulos, at Monash University, Melbourne. Her expertise is in the study of G protein coupled receptors (GPCRs), particularly the family B subclass of GPCRs and the principal interest of her research is towards understanding the modes of their regulation in an effort to identify novel approaches for drug discovery. Her research interests encompass differential signalling, interaction of receptors with regulatory accessory proteins, allosterism and the structure and mechanism by which these GPCRs are activated. She is an author of 18 scientific articles, 2 book chapters and is a reviewer of four international journals.

Symposium 3: Emerging trends in dose individualisation in clinical practice

Assoc Prof Jennifer Martin, The University of Queensland

A/Prof Martin is a practising clinical pharmacologist and academic physician in Brisbane. Her physician and pharmacology training was undertaken in Christchurch and Melbourne, health economic training in Oxford and and a PhD and postdoctoral employment at St Vincent's Hospital and the Walter and Eliza Hall Institute. Her research interests are quality use of medicines, dosing in obesity, pharmacogenetics and quality use of medicines.

Prof Elizabeth Phillips, Institute for Immunology and Infectious Diseases

Elizabeth Phillips, MD, FRCPC, FRACP is a researcher and clinician who runs programs in drug hypersensitivity at the Institute for Immunology and Infectious Diseases, Murdoch University and Royal Perth Hospital, Sir Charles Gairdner Hospital, Perth, Western Australia. She earned her MD from the University of Alberta with fellowships in Internal Medicine, Infectious Diseases, Clinical Pharmacology and Medical Microbiology from the University of Toronto. Research has focused on drug hypersensitivity, HIV pharmacology and the widespread application of pharmacogenetic testing to clinical practice. The research on abacavir hypersensitivity which has created a road map for the application of pharmacogenetic tests from discovery through to clinical translation. Current research is focusing on elucidating the immunopathogenesis of drug hypersensitivity reactionspre-clinical pharmacogenomic screening strategies to inform drug development and design.

Dr Paul Chin, University of Otago, NZ

I am completing advanced training in clinical pharmacology with the RACP as at December 2012. As part of this, I have been awarded a HRC Clinical Research Fellowship to undertake a PhD. The overarching goal is to find the best ways of utilising drug clearance for clinical dosing individualisation. Particular drugs of interest include dabigatran etexilate and gentamicin, which are renally eliminated.

Assoc Prof Michael Neely, University of Southern California, USA

Dr. Neely is an Associate Professor of Pediatrics at the University of Southern California (USC). Dr. Neely's research and clinical interests are in personalized medicine, including population pharmacokinetic and pharmacodynamic modeling, simulation, pharmacogenomics, developmental pharmacology, and most importantly, use of models to optimize therapy for individual patients. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on antiviral, antiretroviral and antifungal compounds, he has experience with other therapeutic areas. He is currently the Director of the USC Laboratory of Applied Pharmacokinetics, working with multidisciplinary faculty collaborators in the Departments of Pediatrics, Medicine, Preventive Medicine, Mathematics, Pharmacology and Pharmaceutical Sciences, and the National Aeronautical and Space Association's Jet Propulsion Laboratory. He recently earned a Master's of Science in Clinical and Biomedical Investigations at USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling, and he serves on the United States Food and Drug Administration Anti-infective Drug Advisory Committee. He is a member of the prestigious Society for Pediatric Research. Dr. Neely has just completed an NIH career development award, and is the principle investigator on two new NIH R01 awards to develop new pharmacokinetic modeling techniques and trial designs, and to investigate dose optimization of vancomycin and voriconazole for individual patients. He is also a recipient of a 2011 Ideas Empowered grant from the USC Stevens Institute to join his lab's dose optimization software with electronic medical record systems on the road to a fully commercial product. He has over 60 publications in peer-reviewed journals, and has presented his work at numerous conferences worldwide.

Symposium 4: The patient journey

Ms Aileen Collier, University Technology Sydney

(PhD Candidate)
BSc (Hons) Nursing (University of Abertay, Dundee), RN
Post Grad Dip (Palliative Care) Dundee University
Aileen has extensive clinical and project experience in palliative and end of life care having worked in a diverse range of settings in the UK, Lao P.D.R as well as Australia. Aileen's research undergirds her commitment to her practical work, with moral and pragmatic questions and proposals always remaining anchored to clinical 'realities'. Her interest is in practice-based research that fosters safety and quality of end of life care in mainstream health care settings. Aileen's other passion is for education in her field and she contributes to the Palliative and Supportive Services post-graduate programmes at Flinders University, S.A.

Ms Karen Kaye, NPS MedicineWise

Karen has been an Executive Manager at NPS since 2008 and leads the planning and design of NPS information and education services for both health professionals and consumers. Karen has practised as a pharmacist in Australia and the UK in hospital, community, industry, academic and professional settings. Prior to joining NPS she led the NSW Therapeutic Advisory Group as Executive Officer and was Director of Pharmacy at Royal Prince Alfred Hospital. She maintains a strong interest in pharmacy practice and clinical practice improvement, particularly across interfaces of care, and the empowerment of consumers to be active partners in decisions about medicines and other health choices.

Symposium 5: Metabolites and medication safety

E/Prof Geoff Tucker, Simcyp Ltd

Geoff is Emeritus Professor of Clinical Pharmacology at the University of Sheffield, UK; Ph.D (1967) from the University of London and an honorary D.Sc (2006) from the University of Uppsala. He has published widely in clinical and theoretical pharmacokinetics, pharmacogenetics, drug metabolism, drug-drug interactions and the pharmacology of drugs used in anaesthesia. Geoff is Chairman of the Board of Pharmaceutical Sciences of the International Pharmaceutical Federation (FIP), Fellow of the Royal College of Anaesthetists, the Royal College of Physicians Edinburgh), the Faculty of Pharmaceutical Medicine, Royal College of Physicians UK, the British Pharmacological Society and the British Toxicological Society. Founder of Simcyp Ltd, a spin-out company specialising in predictive pharmacokinetics.

Dr Kashyap Patel, Monash University

Dr Kashyap Patel is a Research Fellow at Monash University, Melbourne, Australia. He received his PhD from The University of Auckland (NZ) in 2010, where he developed a spatially-resolved pharmacokinetic/pharmacodynamic model for the hypoxia-activated anticancer prodrug PR-104. In 2010, Kashyap undertook a post-doctoral fellowship at the University of Queensland under the supervision of Professor Carl M. Kirkpatrick. During this tenure, he developed population pharmacokinetic/pharmacodynamic models for antifungal drugs and for a novel class of cardio-endocrine hormones. His current research focuses on modelling the effects of antimalarials, antimicrobials and drugs used in the treatment of sepsis.

Dr Michael Wiese, The University of South Australia

Dr Michael Wiese is a Senior Lecturer at the University of South Australia, School of Pharmacy, having worked as a clinical pharmacist for 10 years prior to receiving his PhD in 2007, upon which he took up his current position at the University of South Australia. He currently teaches into the second and third years of the Bachelor of Pharmacy program, and has research interest in the optimisation of conventional DMARDs in the treatment of Rheumatoid Arthritis via the use of pharmacogenomics and therapeutic drug monitoring, and in the underlying pathophysiology and diagnosis of drug allergies.

Craig Lindsley, Vanderbilt University, USA

Symposium 6: Ion channels in drug discovery: developing safer medications

Dr Lachlan Rash, The University of Queensland

Lachlan completed his PhD in the Department of Pharmacology at Monash University where he studied the pharmacological activity of Australian spider venoms. After a brief period as an Associate Lecturer at Monash, he moved to France on an INSERM / NH&MRC Post-Doctoral Fellowship to work in the group of Prof. Michel Lazdunski, who discovered the family of acid-sensing ion channels (ASICs) and the first venom peptides that potently block them. There, he worked on understanding how these venom peptides modulate ASIC function. Lachlan is currently an NH&MRC funded-senior research officer working at the Institute for Molecular Bioscience in Brisbane on the discovery and molecular pharmacology of venom peptides that modulate ion channels involved in pain and neurodegeneration.

Prof Peter McIntyre, The University of Melbourne

Professor Peter McIntyre is the deputy Head of the Health Innovations Research Institute at RMIT University. He obtained his Ph.D. in Biochemistry and Molecular Biology from LaTrobe University in 1985 and trained as a post doctoral fellow at the Walter and Eliza Hall Institute and at the Imperial Cancer Research Fund (now Cancer Research UK) laboratories in London. He is an authority on the regulation and function of transient receptor potential (TRP) ion channels that control pain transmission. He led a pre-clinical research team at the Novartis Institute for Medical Sciences (NIMS) at University College London, where his group discovered TRPA1, TRPM8 and TRPV3. He has extensive expertise in the molecular and pharmacological characterization of ion channels, in drug discovery, validation of therapeutic targets, and drug development and was a drug discovery program leader between 1999 and 2004 and became Head of the Biology Section of NIMS.

He relocated to from Industry to Academia in 2005 when he became Chairman and Head of the Department of Pharmacology at the University of Melbourne during a period of great change. He runs a relatively young but vibrant research group and collaborates widely. He shares NHMRC grants with researchers at Monash University, The Murdoch Institute and Macquarie University. He joined RMIT University as Deputy Director of the Health Innovations Research Institute in 2012. His expertise in pain and channel function will facilitate examination of the mechanisms by which TRPV4 is activated in pain and his expertise in drug discovery and development will enable evaluation of the therapeutic potential of receptor agonists and antagonists to treat pain and inflammation.

Prof Mary Chebib, The University of Sydney

Prof Mary Chebib obtained her PhD in 1994 from Griffith University. After a 6 year post-doc position, she commenced an academic position in the Faculty of Pharmacy the University of Sydney. She has a number of awards including Faculty of Pharmacy Higher Degree Supervision Award (2007), RACI's BIOTA Holdings Award in Medicinal Chemistry and ASCEPT Johnson & Johnson New Investigator Award. She has over 80 international peer reviewed articles and 3 International patents. Her research focuses on the molecular pharmacology and chemistry of GABA and nicotinic acetylcholine receptors and their involvement in anxiety, sleep disorders and learning and memory. Part of her interests is to develop subtype selective agents in order to minimize unwanted side effects when targeting these receptors.

Dr Tamara Paravicini, The University of Queensland

Dr Paravicini received her PhD in pharmacology from the University of Melbourne in 2005 before undertaking postdoctoral training at the Ottawa Health Research Institute. Her research centres on identifying the molecular mechanisms underlying cardiovascular remodelling and dysfunction in hypertension and diabetes. More recently, her work has focused on understanding the role of the channel-enzymes TRPM6 and TRPM7 in cardiovascular disease. She is a past recipient of fellowships from the Foundation for High Blood Pressure Research and the National Heart Foundation, and currently holds a position as a Lecturer in the School of Biomedical Sciences at the University of Queensland.

Symposium 7: Drug safety-clinical pharmacology at the epicentre

Dr Yoon Loke, University of East Anglia, UK

Dr Yoon K Loke is Senior Lecturer in Clinical Pharmacology at the University of East Anglia, and Co-Convenor of the Cochrane Adverse Effects Methods Group. He has extensive experience in conducting systematic reviews of adverse effects, and is the lead author of Chapter 14 in the Cochrane Handbook of Systematic Reviews. His main interests are in assessing harmful effects from drugs such as the proton pump inhibitors, thiazolidinediones, and inhalers for airway disease. He also serves as Deputy Chair of the National Institute of Health Research Health Technology Assessment Pharmaceutics Panel, and European Editor for the British Journal of Clinical Pharmacology. Dr Loke's main interest is on how systematic review methodology can be used to answer clinically relevant questions on the adverse effects of medication.

Prof Elizabeth Phillips, Murdoch University

Elizabeth Phillips, MD, FRCPC, FRACP is a researcher and clinician who runs programs in drug hypersensitivity at the Institute for Immunology and Infectious Diseases, Murdoch University and Royal Perth Hospital, Sir Charles Gairdner Hospital, Perth, Western Australia. She earned her MD from the University of Alberta with fellowships in Internal Medicine, Infectious Diseases, Clinical Pharmacology and Medical Microbiology from the University of Toronto. Research has focused on drug hypersensitivity, HIV pharmacology and the widespread application of pharmacogenetic testing to clinical practice. The research on abacavir hypersensitivity which has created a road map for the application of pharmacogenetic tests from discovery through to clinical translation. Current research is focusing on elucidating the immunopathogenesis of drug hypersensitivity reactionspre-clinical pharmacogenomic screening strategies to inform drug development and design.

Prof David Le Couteur, The University of Sydney

David Le Couteur is Professor of Geriatric Medicine at the University of Sydney, Director of the Centre for Education and Research on Ageing (CERA), Director of the Biogerontology Laboratory of the ANZAC Medical Research Institute and Senior Staff Specialist Physician in Geriatric Medicine at the Concord RG Hospital in Sydney. He is president of the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT). His current research focuses on the effects of old age on liver pharmacology and physiology; the discovery of age-related pseudocapillarization of the liver sinusoid and its effects on liver metabolism and drug clearance; and his clinical interest relates to geriatric pharmacology and the application of evidence based medicine to older people.

Dr Kathlyn Ronaldson, Monash University



Dr Kathlyn Ronaldson is a Senior Research Fellow in Drug Epidemiolgy in the Department of Epidemiology and Preventive Medicine at Monash University. In recent years she has been using a case-control design to investigate clozapine-induced and myocarditis. This methodology has permitted characterisation of the adverse reaction, development of a monitoring protocol and identification of risk factors. She also has an interest in regulatory processes and spontaneous reporting having spent 17 years working in adverse drug reactions for the regulator first in New Zealand and then in Australia. She has a PhD in chemistry from Waikato University, Hamilton, New Zealand and an MPH from Monash University.

Symposium 8: Novel drug delivery strategies with clinical applications

Prof Hak-Kim Chan, The University of Sydney

Hak-Kim Chan, Professor in Pharmaceutics, is leading the Respiratory Research Theme and the Advanced Drug Delivery Group at the Faculty of Pharmacy, University of Sydney. He graduated from USyd (Ph.D. 1988 and D.Sc. 2009), was a postdoc at the University of Minnesota in 1988 – 1989 and a scientist at Genentech Inc in 1992 – 1995. His research focuses on inhalation drug delivery, ranging from powder production by novel processes, particle engineering and aerosol formulation to scintigraphic imaging of lung deposition and clinical outcomes. He has over 250 scientific publications on inhalation formulation and drug delivery (with over 4900 citations) and holds seven patents. He is an executive editor of Advanced Drug Delivery Reviews, Fellow of the AAPS, and Vice President of the Asian Federation for Pharmaceutical Sciences.

Prof Arto Urtti, University of Helsinki

Arto Urtti received pharmaceutical education and Ph.D. at University of Kuopio, Finland, where he served as professor until joining Centre for Drug Research at University of Helsinki as director in 2005. He carried out post-doctoral and sabbatical research at Universities of Kansas and California (San Francisco). His main research fields are ocular drug delivery and pharmacokinetics. He has received several awards including AAPS Fellowship. He has educated 33 PhDs and served as expert in funding agencies of EU and 13 countries. He has published about 250 publications that were cited more than 5500 times.

Symposium 9: Joint ASCEPT-APSA education symposium

Prof Kathie Knights PhD, Flinders University, South Australia

Kathie completed a BSc Honours degree in biochemistry and pharmacology in London while working at Guy's and Kings College Hospitals. She obtained her PhD from Flinders University in 1984 and a Graduate Certificate in Tertiary Education, 1997. In 1989 she was appointed as a Lecturer in the Department of Clinical Pharmacology at Flinders University and was promoted to Professor in 2008. In 2007 she was awarded an Australian Carrick Citation for outstanding contribution to student learning and in 2010 the ASCEPT Teaching Excellence Award. A member of ASCEPT since 1980 she served as Councillor and Treasurer (1997-2000) and as ASCEPT President (2008-2009). Additionally, she has served as a Councillor (2008-2011) of the International Society for the Study of Xenobiotics (ISSX). Currently she is a member of the BPS, the Drug Metabolism Section of IUPHAR and the National Committee for Biomedical Sciences of the Australian Academy of Science. The main focus of her research is the enzymology of drug metabolism and in particular the metabolism and renal and cardiovascular toxicity of non-steroidal anti-inflammatory drugs. Other research areas include the inter-relationships between xenobiotic and endobiotic metabolism and the in vitro–in vivo correlation of drugs eliminated by glucuronidation. To date she has published >150 journal articles and abstracts in peer reviewed international journals, five book chapters and is currently a member of the editorial boards of Drug Metabolism Reviews and the British Journal of Clinical Pharmacology. She is co-author of the highly successful text *Pharmacology for Health Professionals*. In addition to her research Professor Knights is actively involved in the education of health professionals including medical and paramedic students and Nurse Practitioners.

Dr Richard Loiacono, Monash University



Richard Loiacono is a Senior Lecturer in Pharmacology and Deputy Convenor of the Biomedical Science Degree Course at Monash University. Richard teaches pharmacology across several degree courses including science, biomedical science and medicine. Richard's research focus is in neuropharmacology and behavioural paradigms for neurological disorders. He keenly tries to make neuropharmacology content accessible for students across the course he teaches into, engaging the students and challenging their knowledge. He is a past winner of the Faculty of Medicine Teaching award and nominated for a Vice Chancellors award in Teaching.

Dr Hilary Lloyd, The University of Sydney



Hilary Lloyd is a senior lecturer at the University of Sydney. Hilary has 20 years teaching experience in most areas of pharmacology. In 2003, she introduced problem-based learning tutorials into 2nd year pharmacology, which continue to receive positive feedback from students. She is a keen advocate of group work and has published two papers and one book chapter on students' perception of group learning. She was the project manager of an ALTC funded project "Ensuring Quality Graduates of Pharmacology" (final report 2010). She has recently completed an eLearning course at Sydney University (Developing Integrated eLearning Environments in Higher Education) an area she is keen to develop so that students can gain the most from their face-to-face and on-line learning environments.

Symposium 10: Sex differences in chronic diseases: implications for future therapies

Assoc Prof Anthony J. Hannan, University of Melbourne

Anthony Hannan received his undergraduate training and PhD from the University of Sydney. He was then awarded a Nuffield Medical Fellowship at the University of Oxford, where he subsequently held other research positions. Dr Hannan is an ARC Future Fellow (FT3), Principal Research Fellow and head of Neural Plasticity, Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre. He is also an Honorary NHMRC Senior Research Fellow and Associate Professor at the University of Melbourne. His laboratory investigates gene-environment interactions and experience-dependent plasticity in the healthy and diseased brain. An outline of current research activities can be found at: www.florey.edu.au/research/neural-plasticity.

Assoc Prof Kate Denton, Monash University

Associate Professor Kate Denton is a Senior Research Fellow (NHMRC) at Monash University, Melbourne, Australia. An integrative physiologist her research focuses on cardiovascular and renal physiology, with a particular emphasis on the regulation of arterial pressure. Current projects examine sex-differences in the role of the renin-angiotensin in arterial pressure regulation and the impact of a chronic hypertension during pregnancy on offspring.
A/Prof Denton is the program convenor for ISH 2012, has been the program secretary for the Australian High Blood Pressure Research Council (2008-2010), on the editorial board of the Journal of Hypertension, guest editor for the American Journal of Physiology and on numerous selection committees for nationally competitive funding.

Dr Amanda Sampson, Baker IDI Heart and Diabetes Institute

Dr Amanda Sampson completed her PhD in 2008 at the department of Physiology, Monash University Clayton. Her research revealed the first evidence that low dose AngII, a potent vasoconstrictor, reduced arterial pressure in females via an AT2R-dependent mechanism. Following this work, Dr Sampson completed a 2 year postdoctoral appointment in Prof. Anna Dominiczakï's genetics laboratory at the University of Glasgow, Scotland. Dr Sampson has continued her research into sex differences in blood pressure regulation and is currently investigating the role of the Y chromosome in blood pressure regulation at the Baker IDI Heart and Diabetes Institute.

Prof Lea Delbridge, The University of Melbourne

Professor Lea Delbridge heads the Cardiac Phenomics Laboratory in the Department of Physiology at the University of Melbourne. Her research focus is to understand structural and functional cardiopathology in different forms of hypertrophic cardiomyopathy associated with hormonal disturbances. Lea is World Council Member and President of the Australasian Section Council of the International Society of Heart Research (ISHR), a recent Council member for the Australian Physiological Society (AuPS), an elected Fellow of the Cardiac Soc of Aust & NZ and appointed to the Cardiac Society of Australia &NZ Scientific Committee. She is also an editorial board member for a number of international journals, including J Molecular & Cellular Cardiology and the Am J Physiol (Heart.)

Prof Fadi Charchar, University of Ballarat

Fadi Charchar graduated from Melbourne University (PHD) 1998 and is currently Associate Dean (Research) at the University of Ballarat. He was a Wellcome Trust Research Fellow at University of Glasgow and a BHF Lecturer at the University of Leicester. His research interests centers on molecular genetics of complex disease. This includes the Genetics of cardiovascular diseases, sexual dimorphism of cardiovascular risk and the contribution of changes in genomic structure to disease. He has recently been awarded the Okamoto Young Investigator prize for his research on the Y sex chromosome and coronary artery disease.

Symposium 11: Medication safety – systems and practice

Prof Richard Day, St Vincent's Hospital

Richard Day is Professor of Clinical Pharmacology, UNSW and St Vincent's Hospital and is a Clinical Pharmacologist and Rheumatologist. He teaches clinical pharmacology, therapeutics and principles of quality use of medicines (QUM) to medical students at UNSW. He co-founded and heads the Masters in Drug Development at UNSW. His research includes the pharmacotherapy of gout, diabetes, infectious diseases and psychotic disease and innovative methods of achieving the safer use of medicines. He was chairman of PHARM that advised the Federal Government of Australia on achieving QUM. He is Immediate Past President of the DIA, an international organization dedicated to the enhancement of the development of needed medicines world-wide. He co-chairs the Medication Reference group for NeHTA and chairs the Medication Expert Advisory Committee for NSW.

Prof Emily Banks, Australian National University

Professor Emily Banks is a medically trained epidemiologist with interest and expertise in large scale cohort studies, pharmacoepidemiology, women's health, and healthy ageing. She is currently the Scientific Director of the 45 and Up Study, Head of Chronic Disease Epidemiology at the National Centre for Epidemiology and Population Health and Chair of the Advisory Committee on the Safety of Medicines.

Dr Romano Fois, The University of Sydney